{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:52:55Z","timestamp":1790844775171,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12943-018-0795-z","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:35:22Z","timestamp":1518701722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Role of the HGF\/c-MET tyrosine kinase inhibitors in metastasic melanoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Lucia","family":"Demkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-6659","authenticated-orcid":false,"given":"Lucia","family":"Kucerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"795_CR1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670\u201391.","journal-title":"Cell"},{"key":"795_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","volume":"63","author":"C Garbe","year":"2016","unstructured":"Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos AJ, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer. 2016;63:201\u201317.","journal-title":"Eur J Cancer"},{"key":"795_CR3","first-page":"342","volume":"11","author":"Z Mur\u00e1rov\u00e1","year":"2016","unstructured":"Mur\u00e1rov\u00e1 Z, Boreck\u00e1 D. Mal\u00edgny melan\u00f3m \u2013 etiopatogen\u00e9za, klinick\u00fd obraz, diagnostika a mana\u017ement pacienta. Onkol\u00f3gia. 2016;11:342\u20137.","journal-title":"Onkol\u00f3gia"},{"key":"795_CR4","first-page":"144","volume":"4","author":"M Bobrovsk\u00e1","year":"2009","unstructured":"Bobrovsk\u00e1 M, Minarikov\u00e1 E, Plank L. Diagnostika mal\u00edgneho melan\u00f3mu. Onkol\u00f3gia. 2009;4:144\u20138.","journal-title":"Onkol\u00f3gia"},{"key":"795_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","volume":"46","author":"C Garbe","year":"2010","unstructured":"Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270\u201383.","journal-title":"Eur J Cancer"},{"key":"795_CR6","unstructured":"Benca J, Havr\u00e1nkov\u00e1 M, Hlavat\u00e1 Z, Pobij\u00e1kov\u00e1 M, Sieberov\u00e1 G, \u0160\u00e1lek T. Mana\u017ement pacientov s mal\u00edgnym melan\u00f3mom ko\u017ee. In: Metodick\u00fd list \u00dastrednej komisie racion\u00e1lnej farmakoterapie a liekovej politiky MZ SR, vol. 152012. 2012;15:1-8."},{"key":"795_CR7","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2015;26:v126\u201332.","journal-title":"Ann Oncol"},{"key":"795_CR8","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30.","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"795_CR9","first-page":"351","volume":"11","author":"S Urban\u010dek","year":"2016","unstructured":"Urban\u010dek S. Stru\u010dn\u00fd preh\u013ead farmakoterapie metastatick\u00e9ho melan\u00f3mu. Onkol\u00f3gia. 2016;11:351\u20136.","journal-title":"Onkol\u00f3gia"},{"key":"795_CR10","doi-asserted-by":"crossref","unstructured":"Kircher DA, Silvis MR, Cho JH, Holmen SL. Melanoma brain metastasis: mechanisms, models, and medicine. Int J Mol Sci. 2016;17:1-29.","DOI":"10.3390\/ijms17091468"},{"key":"795_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274\u201384.","journal-title":"Nat Rev Cancer"},{"key":"795_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molmed.2007.10.004","volume":"13","author":"M Yilmaz","year":"2007","unstructured":"Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med. 2007;13:535\u201341.","journal-title":"Trends Mol Med"},{"key":"795_CR13","first-page":"293","volume":"1796","author":"TR Geiger","year":"2009","unstructured":"Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796:293\u2013308.","journal-title":"Biochim Biophys Acta"},{"key":"795_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.oraloncology.2014.04.004","volume":"50","author":"YC Lim","year":"2014","unstructured":"Lim YC, Kang HJ, Moon JH. C-met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol. 2014;50:633\u20139.","journal-title":"Oral Oncol"},{"key":"795_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ceb.2015.06.004","volume":"36","author":"AG Clark","year":"2015","unstructured":"Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13\u201322.","journal-title":"Curr Opin Cell Biol"},{"key":"795_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1541-7786.MCR-10-0139","volume":"8","author":"M Yilmaz","year":"2010","unstructured":"Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629\u201342.","journal-title":"Mol Cancer Res"},{"key":"795_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.semcancer.2012.03.006","volume":"22","author":"D Spano","year":"2012","unstructured":"Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol. 2012;22:234\u201349.","journal-title":"Semin Cancer Biol"},{"key":"795_CR18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.cell.2011.11.016","volume":"147","author":"P Friedl","year":"2011","unstructured":"Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992\u20131009.","journal-title":"Cell"},{"key":"795_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450\u201364.","journal-title":"Nat Med"},{"key":"795_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329\u201335.","journal-title":"Nature"},{"key":"795_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10555-010-9225-4","volume":"29","author":"G Pani","year":"2010","unstructured":"Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev. 2010;29:351\u201378.","journal-title":"Cancer Metastasis Rev"},{"key":"795_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2004.09.011","volume":"6","author":"A Tacconelli","year":"2004","unstructured":"Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6:347\u201360.","journal-title":"Cancer Cell"},{"key":"795_CR24","doi-asserted-by":"publisher","unstructured":"Herna\u0301ndez-Caballero ME. Molecular Mechanisms of Metastasis: Epithelial-Mesenchymal Transition, Anoikis and Loss of Adhesion, Carcinogenesis, Dr. Kathryn Tonissen (Ed.), InTech, London, SE19SG United Kingdom. https:\/\/doi.org\/10.5772\/55399 .","DOI":"10.5772\/55399"},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"795_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/labinvest.2011.50","volume":"91","author":"SD Girouard","year":"2011","unstructured":"Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Investig. 2011;91:647\u201364.","journal-title":"Lab Investig"},{"key":"795_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-433-3","volume-title":"Diagnostic and prognostic biomarkers and therapeutic targets in melanoma","author":"MJ Murphy","year":"2012","unstructured":"Murphy MJ. Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. New York: Springer; 2012."},{"key":"795_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4149\/neo_2016_403","volume":"63","author":"Z Kozovska","year":"2016","unstructured":"Kozovska Z, Gabrisova V, Kucerova L. Malignant melanoma: diagnosis, treatment and cancer stem cells. Neoplasma. 2016;63:510\u20137.","journal-title":"Neoplasma"},{"key":"795_CR29","doi-asserted-by":"crossref","unstructured":"Brinckerhoff CE. Cancer stem cells (CSCs) in melanoma: There's smoke, but is there fire? J Cell Physiol. 2017;232:2674-78.","DOI":"10.1002\/jcp.25796"},{"key":"795_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345\u20139.","journal-title":"Nature"},{"key":"795_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/jid.2010.285","volume":"131","author":"A Fusi","year":"2010","unstructured":"Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A, Maisel M, Keilholz U. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Investig Dermatol. 2010;131:487\u201394.","journal-title":"J Investig Dermatol"},{"key":"795_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1677\/erc.0.0080161","volume":"8","author":"E Zwick","year":"2001","unstructured":"Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001;8:161\u201373.","journal-title":"Endocr Relat Cancer"},{"key":"795_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine Kinases. Cell. 2010;141:1117\u201334.","journal-title":"Cell"},{"key":"795_CR34","doi-asserted-by":"crossref","unstructured":"Herraiz C, et al. Functional interplay between secreted ligands and receptors in melanoma. Semin Cell Dev Biol. 2017. http:\/\/dx.doi.org\/10.1016\/j.semcdb.2017.06.021 . [Epub ahead of print].","DOI":"10.1016\/j.semcdb.2017.06.021"},{"key":"795_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ceb.2007.02.010","volume":"19","author":"SR Hubbard","year":"2007","unstructured":"Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007;19:117\u201323.","journal-title":"Curr Opin Cell Biol"},{"key":"795_CR36","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:S7\u2013S19.","journal-title":"Ther Adv Med Oncol"},{"key":"795_CR37","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.1073\/pnas.1016912108","volume":"108","author":"Y Li","year":"2011","unstructured":"Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG, et al. C-met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 2011;108:9951\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"795_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1349-7006.2012.02279.x","volume":"103","author":"S Yano","year":"2012","unstructured":"Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 2012;103:1189\u201394.","journal-title":"Cancer Sci"},{"key":"795_CR39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bjc.2016.419","volume":"116","author":"A Daud","year":"2017","unstructured":"Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116:432\u201340.","journal-title":"Br J Cancer"},{"key":"795_CR40","doi-asserted-by":"publisher","first-page":"e2578","DOI":"10.1038\/cddis.2016.403","volume":"8","author":"P Bendinelli","year":"2017","unstructured":"Bendinelli P, Maroni P, Matteucci E, Desiderio MA. Epigenetic regulation of HGF\/met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma. Cell Death Dis. 2017;8:e2578.","journal-title":"Cell Death Dis"},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","volume":"4","author":"C Birchmeier","year":"2003","unstructured":"Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/376768a0","volume":"376","author":"F Bladt","year":"1995","unstructured":"Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 1995;376:768\u201371.","journal-title":"Nature"},{"key":"795_CR43","first-page":"537","volume":"12","author":"WG Jiang","year":"1997","unstructured":"Jiang WG, Hiscox S. Hepatocyte growth factor\/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol. 1997;12:537\u201355.","journal-title":"Histol Histopathol"},{"key":"795_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0955-2235(91)90014-U","volume":"3","author":"T Nakamura","year":"1991","unstructured":"Nakamura T. Structure and function of hepatocyte growth factor. Progress in growth factor research. 1991;3:65\u201387.","journal-title":"Progress in growth factor research"},{"key":"795_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biocel.2014.01.009","volume":"49","author":"R Barrow-McGee","year":"2014","unstructured":"Barrow-McGee R, Kermorgant S. Met endosomal signalling: in the right place, at the right time. Int J Biochem Cell Biol. 2014;49:69\u201374.","journal-title":"Int J Biochem Cell Biol"},{"key":"795_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0378-1119(91)90080-U","volume":"102","author":"T Seki","year":"1991","unstructured":"Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene. 1991;102:213\u20139.","journal-title":"Gene"},{"key":"795_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1359-6101(01)00029-6","volume":"13","author":"G Maulik","year":"2002","unstructured":"Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Maulik role of the hepatocyte growth factor receptor, c-met, in oncogenetics and potencial for therapeucic inhibition. Cytokine Growth Factor Rev. 2002;13:41\u201359.","journal-title":"Cytokine Growth Factor Rev"},{"key":"795_CR48","first-page":"6495793","volume":"2016","author":"Q Tan","year":"2016","unstructured":"Tan Q, Hu J, Yu X, Guan W, Lu H, Yu Y, Zang G, Tang Z. The role of IL-1 family members and Kupffer cells in liver regeneration. Biomed Res Int. 2016;2016:6495793.","journal-title":"Biomed Res Int"},{"key":"795_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0378-1119(98)00264-9","volume":"215","author":"Y Liu","year":"1998","unstructured":"Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene. 1998;215:159\u201369.","journal-title":"Gene"},{"key":"795_CR50","doi-asserted-by":"publisher","first-page":"18056","DOI":"10.3390\/ijms140918056","volume":"14","author":"JC Samame Perez-Vargas","year":"2013","unstructured":"Samame Perez-Vargas JC, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, et al. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 2013;14:18056\u201377.","journal-title":"Int J Mol Sci"},{"key":"795_CR51","first-page":"13","volume":"7","author":"I Garajov\u00e1","year":"2015","unstructured":"Garajov\u00e1 I, Giovannetti E, Biasco G, Peters GJ. C-met as a target for personalized therapy. Translational Oncogenomics. 2015;7:13\u201331.","journal-title":"Translational Oncogenomics"},{"key":"795_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89\u2013103.","journal-title":"Nat Rev Cancer"},{"key":"795_CR53","first-page":"359","volume":"5","author":"H Zhu","year":"1994","unstructured":"Zhu H, Naujokas MA, Park M. Receptor chimeras indicate that the met tyrosine kinase mediates the motility and morphogenic responses of hepatocyte growth\/scatter factor. Cell Growth Differ. 1994;5:359\u201366.","journal-title":"Cell Growth Differ"},{"key":"795_CR54","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood.V80.10.2454.2454","volume":"80","author":"TE Kmiecik","year":"1992","unstructured":"Kmiecik TE, Keller JR, Rosen E, Vande Woude GF. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood. 1992;80:2454\u20137.","journal-title":"Blood"},{"key":"795_CR55","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/emmm.201000085","volume":"2","author":"F B\u00f6hm","year":"2010","unstructured":"B\u00f6hm F, K\u00f6hler UA, Speicher T, Werner S. Regulation of liver regeneration by growth factors and cytokines. EMBO Molecular Medicine. 2010;2:294\u2013305.","journal-title":"EMBO Molecular Medicine"},{"key":"795_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.200701086","volume":"177","author":"J Chmielowiec","year":"2007","unstructured":"Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S, Wehland J, Birchmeier C, Birchmeier W. C-met is essential for wound healing in the skin. J Cell Biol. 2007;177:151\u201362.","journal-title":"J Cell Biol"},{"key":"795_CR57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","volume":"142","author":"CR Maroun","year":"2014","unstructured":"Maroun CR, Rowlands T. The met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014;142:316\u201338.","journal-title":"Pharmacol Ther"},{"key":"795_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-016-0366-y","volume":"9","author":"BQ Lam","year":"2016","unstructured":"Lam BQ, Dai L, Qin Z. The role of HGF\/c-MET signaling pathway in lymphoma. J Hematol Oncol. 2016;9:135.","journal-title":"J Hematol Oncol"},{"key":"795_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-015-0367-4","volume":"14","author":"HH Cao","year":"2015","unstructured":"Cao HH, Cheng CY, Su T, Fu XQ, Guo H, Li T, Tse AK, Kwan HY, Yu H, Yu ZL. Quercetin inhibits HGF\/c-met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 2015;14:103.","journal-title":"Mol Cancer"},{"key":"795_CR60","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/gt.2014.66","volume":"21","author":"L Kucerova","year":"2014","unstructured":"Kucerova L, Skolekova S, Demkova L, Bohovic R, Matuskova M. Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC\/5FC therapy in human melanoma xenograft model. Gene Ther. 2014;21:874\u201387.","journal-title":"Gene Ther"},{"key":"795_CR61","first-page":"969","volume":"7","author":"RA Parikh","year":"2014","unstructured":"Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014;7:969\u201383.","journal-title":"Onco Targets Ther"},{"key":"795_CR62","doi-asserted-by":"publisher","first-page":"533","DOI":"10.18632\/oncoscience.161","volume":"2","author":"M Zenali","year":"2015","unstructured":"Zenali M. deKay J, Liu Z, Hamilton S, Zuo Z, Lu X, Bakkar R, Mills G, Broaddus R: retrospective review of MET gene mutations. Oncoscience. 2015;2:533\u201341.","journal-title":"Oncoscience"},{"key":"795_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","volume":"27","author":"A Gentile","year":"2008","unstructured":"Gentile A, Trusolino L, Comoglio PM. The met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27:85\u201394.","journal-title":"Cancer Metastasis Rev"},{"key":"795_CR64","first-page":"5462","volume":"63","author":"M Sattler","year":"2003","unstructured":"Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the Oncogenic TPR-MET tyrosine Kinase. Cancer Res. 2003;63:5462\u20139.","journal-title":"Cancer Res"},{"key":"795_CR65","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-06-0776","volume":"13","author":"N Puri","year":"2007","unstructured":"Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. C-met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13:2246\u201353.","journal-title":"Clin Cancer Res"},{"key":"795_CR66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4161\/cbt.29451","volume":"15","author":"D Etnyre","year":"2014","unstructured":"Etnyre D, Stone AL, Fong JT, Jacobs RJ, Uppada SB, Botting GM, Rajanna S, Moravec DN, Shambannagari MR, Crees Z, et al. Targeting c-Met in melanoma. Cancer Biology & Therapy. 2014;15:1129\u201341.","journal-title":"Cancer Biology & Therapy"},{"key":"795_CR67","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","volume":"65","author":"PC Ma","year":"2005","unstructured":"Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, et al. Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non\u2013small cell lung cancer. Cancer Res. 2005;65:1479\u201388.","journal-title":"Cancer Res"},{"key":"795_CR68","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/156800910791190184","volume":"10","author":"I Kenessey","year":"2010","unstructured":"Kenessey I, Keszthelyi M, Kramer Z, Berta J, Adam A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, et al. Inhibition of c-met with the specific small molecule tyrosine Kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 2010;10:332\u201342.","journal-title":"Curr Cancer Drug Targets"},{"key":"795_CR69","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12885-016-2341-y","volume":"16","author":"L Kucerova","year":"2016","unstructured":"Kucerova L, Demkova L, Skolekova S, Bohovic R, Matuskova M. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation. BMC Cancer. 2016;16:308.","journal-title":"BMC Cancer"},{"key":"795_CR70","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","volume":"19","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19:e5\u201311.","journal-title":"Oncologist"},{"key":"795_CR71","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung P-P, et al. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits Cytoreductive antitumor efficacy through Antiproliferative and Antiangiogenic mechanisms. Cancer Res. 2007;67:4408\u201317.","journal-title":"Cancer Res"},{"key":"795_CR72","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","volume":"6","author":"JG Christensen","year":"2007","unstructured":"Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6:3314\u201322.","journal-title":"Mol Cancer Ther"},{"key":"795_CR73","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/1535-7163.MCT-15-0871","volume":"15","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Rex K, Caenepeel S, Yang Y, Zhang Y, Broome MA, Kha HT, Burgess TL, Amore B, Kaplan-Lefko PJ, et al. <em>in vitro<\/em> and <em>in vivo<\/em> activity of AMG 337, a potent and selective MET Kinase inhibitor, in MET-dependent cancer models. Mol Cancer Ther. 2016;15:1568\u201379.","journal-title":"Mol Cancer Ther"},{"key":"795_CR74","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1021\/jm800401t","volume":"51","author":"L Liu","year":"2008","unstructured":"Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, et al. Discovery of a potent, selective, and orally bioavailable c-met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem. 2008;51:3688\u201391.","journal-title":"J Med Chem"},{"key":"795_CR75","doi-asserted-by":"crossref","unstructured":"Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B. Higher levels of c-met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012;84:e525-31.","DOI":"10.1016\/j.ijrobp.2012.06.025"},{"key":"795_CR76","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","volume":"30","author":"Y Kataoka","year":"2012","unstructured":"Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Investig New Drugs. 2012;30:1352\u201360.","journal-title":"Investig New Drugs"},{"key":"795_CR77","doi-asserted-by":"crossref","first-page":"14940","DOI":"10.18632\/oncotarget.3613","volume":"6","author":"H-M Chen","year":"2015","unstructured":"Chen H-M, Tsai C-H, Hung W-C. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2\/3 and TIE-2 signaling. Oncotarget. 2015;6:14940\u201352.","journal-title":"Oncotarget"},{"key":"795_CR78","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","volume":"69","author":"F Qian","year":"2009","unstructured":"Qian F, Engst S, Yamaguchi K, Yu P, Won K-A, Mock L, Lou T, Tan J, Li C, Tam D, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine Kinases. Cancer Res. 2009;69:8009\u201316.","journal-title":"Cancer Res"},{"key":"795_CR79","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-11-0193","volume":"17","author":"KE Torres","year":"2011","unstructured":"Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3943\u201355.","journal-title":"Clin Cancer Res"},{"key":"795_CR80","first-page":"7345","volume":"63","author":"JG Christensen","year":"2003","unstructured":"Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. A selective small molecule inhibitor of c-met Kinase inhibits c-met-dependent phenotypes in vitro and exhibits Cytoreductive antitumor activity in vivo. Cancer Res. 2003;63:7345\u201355.","journal-title":"Cancer Res"},{"key":"795_CR81","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1002\/ijc.26487","volume":"131","author":"C Chattopadhyay","year":"2012","unstructured":"Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of Activated c-met with NRAS-mutated human melanomas: a possible avenue for targeting. Int J Cancer. 2012;131:E56\u201365.","journal-title":"Int J Cancer"},{"key":"795_CR82","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/mc.22418","volume":"55","author":"HK Byeon","year":"2016","unstructured":"Byeon HK, Na HJ, Yang YJ, Kwon HJ, Chang JW, Ban MJ, Kim WS, Shin DY, Lee EJ, Koh YW, et al. C-met-mediated reactivation of PI3K\/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Mol Carcinog. 2016;55:1678\u201387.","journal-title":"Mol Carcinog"},{"key":"795_CR83","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-09-2541","volume":"70","author":"B-S Pan","year":"2010","unstructured":"Pan B-S, Chan GKY, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, et al. MK-2461, a novel multitargeted Kinase inhibitor, preferentially inhibits the activated c-met receptor. Cancer Res. 2010;70:1524\u201333.","journal-title":"Cancer Res"},{"key":"795_CR84","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1158\/0008-5472.CAN-12-2160","volume":"73","author":"B Sennino","year":"2013","unstructured":"Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013;73:3692\u2013703.","journal-title":"Cancer Res"},{"key":"795_CR85","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-12-3459","volume":"19","author":"C Basilico","year":"2013","unstructured":"Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P. Tivantinib (ARQ197) displays Cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res. 2013;19:2381\u201392.","journal-title":"Clin Cancer Res"},{"key":"795_CR86","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368\u201372.","journal-title":"Nature"},{"key":"795_CR87","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","volume":"86","author":"P Sch\u00f6ffski","year":"2017","unstructured":"Sch\u00f6ffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017;86:296\u2013304.","journal-title":"Eur J Cancer"},{"key":"795_CR88","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1200\/jco.2012.30.15_suppl.8531","volume":"30","author":"MS Gordon","year":"2012","unstructured":"Gordon MS, Kluger HM, Shapiro G, Kurzrock R, Edelman G, Samuel TA, Moussa AH, Ramies DA, Laird AD, Schimmoller F, et al. Activity of cabozantinib (XL184) in metastatic melanoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30:8531.","journal-title":"J Clin Oncol"},{"key":"795_CR89","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","volume":"12","author":"O Surriga","year":"2013","unstructured":"Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-met inhibitor, prevents metastasis in a metastatic Uveal melanoma model. Mol Cancer Ther. 2013;12:2817\u201326.","journal-title":"Mol Cancer Ther"},{"key":"795_CR90","doi-asserted-by":"publisher","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","volume":"70","author":"F Shojaei","year":"2010","unstructured":"Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG. HGF\/c-met acts as an alternative Angiogenic pathway in Sunitinib-resistant tumors. Cancer Res. 2010;70:10090\u2013100.","journal-title":"Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-018-0795-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T05:26:09Z","timestamp":1603862769000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-018-0795-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1186\/s12943-018-0795-z","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,19]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}